Cerus (NASDAQ:CERS) was upgraded by stock analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Friday.

Several other research firms have also weighed in on CERS. Zacks Investment Research raised shares of Cerus from a “hold” rating to a “buy” rating and set a $4.00 price objective for the company in a report on Wednesday, November 8th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Cerus in a report on Friday. Cowen set a $6.00 price objective on shares of Cerus and gave the stock a “buy” rating in a report on Thursday, October 5th. BTIG Research reaffirmed a “neutral” rating on shares of Cerus in a report on Friday, December 8th. Finally, ValuEngine raised shares of Cerus from a “strong sell” rating to a “sell” rating in a report on Thursday. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $6.17.

Cerus (CERS) traded up $0.12 during trading hours on Friday, reaching $3.84. 654,890 shares of the company traded hands, compared to its average volume of 587,444. Cerus has a 52-week low of $1.93 and a 52-week high of $4.70. The company has a debt-to-equity ratio of 0.80, a current ratio of 3.71 and a quick ratio of 3.11. The firm has a market capitalization of $452.22, a price-to-earnings ratio of -6.51 and a beta of 1.93.

Cerus (NASDAQ:CERS) last posted its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.12) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.03. The company had revenue of $10.80 million during the quarter, compared to analyst estimates of $11.95 million. Cerus had a negative net margin of 159.35% and a negative return on equity of 142.18%. The company’s revenue was up 5.9% on a year-over-year basis. During the same quarter last year, the business posted ($0.14) earnings per share. equities research analysts expect that Cerus will post -0.57 earnings per share for the current fiscal year.

Several institutional investors have recently modified their holdings of the stock. Elk Creek Partners LLC boosted its stake in Cerus by 6.8% in the third quarter. Elk Creek Partners LLC now owns 6,128,026 shares of the biotechnology company’s stock valued at $16,730,000 after acquiring an additional 388,741 shares during the last quarter. Vanguard Group Inc. boosted its stake in Cerus by 3.9% in the second quarter. Vanguard Group Inc. now owns 4,892,503 shares of the biotechnology company’s stock valued at $12,281,000 after acquiring an additional 184,076 shares during the last quarter. Senvest Management LLC boosted its stake in Cerus by 0.7% in the third quarter. Senvest Management LLC now owns 2,960,398 shares of the biotechnology company’s stock valued at $8,082,000 after acquiring an additional 20,000 shares during the last quarter. Ark Investment Management LLC boosted its stake in Cerus by 126.5% in the second quarter. Ark Investment Management LLC now owns 1,680,925 shares of the biotechnology company’s stock valued at $4,219,000 after acquiring an additional 938,647 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in Cerus by 3.2% in the second quarter. Northern Trust Corp now owns 1,269,773 shares of the biotechnology company’s stock valued at $3,186,000 after acquiring an additional 39,684 shares during the last quarter. 56.44% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Cerus (CERS) Lifted to Sell at BidaskClub” was reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/06/cerus-cers-lifted-to-sell-at-bidaskclub.html.

About Cerus

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Analyst Recommendations for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.